Clinical Trial Update: Open-Label Extension Protocol to SNK01-AD01 Study [Phase 2]

View source ↗

Summary

Open-label extension protocol for the SNK01-AD01 Phase 2 Alzheimer's disease trial is currently recruiting to evaluate longer-term safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SNK01-AD01

Snippet

Sponsor: NKGen Biotech, Inc. | Conditions: Alzheimer Disease | Phase 2 | Status: RECRUITING